The present invention relates to quinoxaline compounds of formula (I), in particular for the treatment of autoimmune disorders and / or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, transplant rejection or lung damage.